BiotechTube

Arformoterol tartrate inhalation solution + Tiotropium

ApprovedTerminated
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Chronic Obstructive Pulmonary Disease (COPD)

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Trial Timeline

Nov 1, 2014 → Sep 14, 2016

NCT ID
NCT02275481

About Arformoterol tartrate inhalation solution + Tiotropium

Arformoterol tartrate inhalation solution + Tiotropium is a approved stage product being developed by Sumitomo Pharma for Chronic Obstructive Pulmonary Disease (COPD). The current trial status is terminated. This product is registered under clinical trial identifier NCT02275481. Target conditions include Chronic Obstructive Pulmonary Disease (COPD).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Obstructive Pulmonary Disease (COPD) were approved

Approved (20) Terminated (2) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02275481ApprovedTerminated

Competing Products

20 competing products in Chronic Obstructive Pulmonary Disease (COPD)

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25